Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepa Jagadeesh

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Leukemia & Lymphoma|May 21, 2025
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 studyBrian T Hill, Pallawi Torka, Francisco Hernandez-Ilizaliturri, et al.
Hematology (Amsterdam, Netherlands)|January 21, 2017
Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab eraAdam G Starr, Paolo F Caimi, PingFu Fu, et al.
Bone Marrow Transplantation|November 17, 2023
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapyMadiha Iqbal, Deepa Jagadeesh, Julio Chavez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin LymphomaSara Singer, Robert Dean, Qiuhong Zhao, et al.
Bone Marrow Transplantation|February 6, 2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomasSara Singer, Nidhi Sharma, Robert Dean, et al.
British Journal of Haematology|July 23, 2016
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab eraAdam G Starr, Paolo F Caimi, PingFu Fu, et al.
British Journal of Haematology|March 9, 2016
Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomesAdam G Starr, Paolo F Caimi, PingFu Fu, et al.
The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
Blood Cancer Journal|January 28, 2026
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Blood Cancer Journal|August 1, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|May 21, 2025
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 studyBrian T Hill, Pallawi Torka, Francisco Hernandez-Ilizaliturri, et al.
Hematology (Amsterdam, Netherlands)|January 21, 2017
Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab eraAdam G Starr, Paolo F Caimi, PingFu Fu, et al.
Bone Marrow Transplantation|November 17, 2023
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapyMadiha Iqbal, Deepa Jagadeesh, Julio Chavez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin LymphomaSara Singer, Robert Dean, Qiuhong Zhao, et al.
Bone Marrow Transplantation|February 6, 2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomasSara Singer, Nidhi Sharma, Robert Dean, et al.
British Journal of Haematology|July 23, 2016
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab eraAdam G Starr, Paolo F Caimi, PingFu Fu, et al.
British Journal of Haematology|March 9, 2016
Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomesAdam G Starr, Paolo F Caimi, PingFu Fu, et al.
The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
Blood Cancer Journal|January 28, 2026
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Blood Cancer Journal|August 1, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.
Pageof 10